Circulating thyroid cancer markers

Abstract

Purpose of review: To describe the progress in the field of circulating markers of thyroid cancer.

Recent findings: Thyroid cancer cells in the circulation can be detected by measuring the mRNA of thyroid-specific genes. Among these, thyroglobulin, and more recently thyroid-stimulating hormone receptor mRNAs' provide high diagnostic sensitivity and specificity for thyroid cancer detection. These markers can be used in synergy with current diagnostic modalities, i.e. fine-needle aspiration and ultrasound, for preoperative diagnosis and serum thyroglobulin measurement for monitoring.

Summary: For the detection of recurrent/residual thyroid cancer, serum thyroglobulin remains the sole circulating marker, but lacks sensitivity and is unreliable in the presence of antithyroglobulin antibodies. The measurement of thyroid-specific mRNA in blood may provide sensitive/specific markers, but significant variability exists among various studies for thyroglobulin mRNA in particular, questioning the validity of this marker. Recent studies have demonstrated the high sensitivity and specificity of thyroid-stimulating hormone receptor mRNA in detecting recurrent/residual disease even in the presence of thyroglobulin antibodies. Fine-needle aspiration biopsy is currently the sole method for evaluating thyroid nodules. Indeterminate fine-needle aspiration cytology is found in approximately 15-30% of specimens. Thyroid-stimulating hormone receptor mRNA measurement in patients with indeterminate fine-needle aspiration may enhance cancer detection and save unnecessary surgeries.